Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Tongue Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Prolactinoma 1Pleural Effusion, Malignant 1Pituitary Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Melanoma 1Lung Neoplasms 1Head and Neck Neoplasms 1Growth Hormone-Secreting Pituitary Adenoma 1Fatigue 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Adenoma, Chromophobe 1Adenoma, Basophil 1Adenoma, Acidophil 1

Interventions

Docetaxel 3Gene Expression Profiling 2vandetanib 1Therapeutics 1Taxes 1Radiotherapy 1Polymerase Chain Reaction 1Microarray Analysis 1Immunohistochemistry 1Hypericum extract LI 160 1Everolimus 1Erlotinib Hydrochloride 1Electrophoresis, Polyacrylamide Gel 1Cisplatin 1Carboplatin 1Biopsy 13-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Salivary Gland Neoplasms × Microarray Analysis × Clear all
NCT01332279 2023-04-04

Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy

Fox Chase Cancer Center

Phase 1 Withdrawn
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡